Ashkan Dashtban

1 month ago | heart.bmj.com | Mohamed Mohamed |Ashkan Dashtban |Sarah Ali |Thomas Oates

DiscussionIn this large, population-based study of simple, evidence-based management for disease pairs across T2D, CKD and HF, we have four findings. First, despite a high comorbidity burden and mortality risk for diseases individually and in combination, major gaps in prevention medications exist. Second, up to half of individuals lacked evidence of BMI or lipid measurement in the past year, with the CKD+HF group most severely affected.